G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genovis AB
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Net Change in Cash
kr21.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Net Change in Cash
-kr104m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Net Change in Cash
-kr64.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Net Change in Cash
-kr131m
CAGR 3-Years
N/A
CAGR 5-Years
-127%
CAGR 10-Years
-32%
MedCap AB (publ)
STO:MCAP
Net Change in Cash
kr93.7m
CAGR 3-Years
N/A
CAGR 5-Years
85%
CAGR 10-Years
12%
M
Magle Chemoswed Holding AB
STO:MAGLE
Net Change in Cash
-kr2.8m
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Net Change in Cash?
Net Change in Cash
21.6m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Net Change in Cash amounts to 21.6m SEK.

What is Genovis AB's Net Change in Cash growth rate?
Net Change in Cash CAGR 1Y
-41%

Over the last year, the Net Change in Cash growth was -41%.

Back to Top